Pfizer submits new drug application to FDA for its COVID-19 treatment Paxlovid
Pfizer announced this morning it submitted a new drug application to formally ask the U.S. Food and Drug Administration for full approval of its COVID-19 treatment Paxlovid for patients who are at high risk for progression to severe illness from the virus.
News 12 Staff
•
Jun 30, 2022, 11:36 AM
•
Updated 664 days ago
Share:
More Stories
0:32
US banning TikTok? Your key questions answered
20h ago0:31
New federal rule would bar 'noncompete' agreements for most employees
21h ago0:26
USDA warns of ground beef that may be contaminated with E.coli
yesterday
Guide: How to host Passover on a budget
5ds ago0:23
Ford recalls over 456,000 Bronco Sport and Maverick cars due to loss of drive power risk
6ds ago2:50
be Well: Celebrate in style with these decorating tips
7ds ago0:32
US banning TikTok? Your key questions answered
20h ago0:31
New federal rule would bar 'noncompete' agreements for most employees
21h ago0:26
USDA warns of ground beef that may be contaminated with E.coli
yesterdayGuide: How to host Passover on a budget
5ds ago0:23
Ford recalls over 456,000 Bronco Sport and Maverick cars due to loss of drive power risk
6ds ago2:50
be Well: Celebrate in style with these decorating tips
7ds agoPfizer announced this morning it submitted a new drug application to formally ask the U.S. Food and Drug Administration for full approval of its COVID-19 treatment Paxlovid for patients who are at high risk for progression to severe illness from the virus.
The submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals.
Paxlovid is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients, 12 years and older, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
The submission provides the longer-term follow-up data necessary for acceptance and potential approval.
